384 related articles for article (PubMed ID: 33972463)
1. The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy.
Kim J; Lee HK
Mol Cells; 2021 May; 44(5):356-362. PubMed ID: 33972463
[TBL] [Abstract][Full Text] [Related]
2. The role of gut microbiota in cancer treatment: friend or foe?
Cheng WY; Wu CY; Yu J
Gut; 2020 Oct; 69(10):1867-1876. PubMed ID: 32759302
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.
Gori S; Inno A; Belluomini L; Bocus P; Bisoffi Z; Russo A; Arcaro G
Crit Rev Oncol Hematol; 2019 Nov; 143():139-147. PubMed ID: 31634731
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota-mediated immunomodulation in tumor.
Liu X; Chen Y; Zhang S; Dong L
J Exp Clin Cancer Res; 2021 Jul; 40(1):221. PubMed ID: 34217349
[TBL] [Abstract][Full Text] [Related]
6. Probiotic species in the modulation of the anticancer immune response.
Marinelli L; Tenore GC; Novellino E
Semin Cancer Biol; 2017 Oct; 46():182-190. PubMed ID: 28844794
[TBL] [Abstract][Full Text] [Related]
7. Do checkpoint inhibitors rely on gut microbiota to fight cancer?
Firwana B; Avaritt N; Shields B; Ravilla R; Makhoul I; Hutchins L; Tackett AJ; Mahmoud F
J Oncol Pharm Pract; 2018 Sep; 24(6):468-472. PubMed ID: 28625074
[TBL] [Abstract][Full Text] [Related]
8. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic cell death: A link between gut microbiota and anticancer effects.
Chen W; Wang S; Wu Y; Shen X; Guo Z; Li Q; Xing D
Microb Pathog; 2020 Apr; 141():103983. PubMed ID: 31954823
[TBL] [Abstract][Full Text] [Related]
11. A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy.
Yang Q; Wang B; Zheng Q; Li H; Meng X; Zhou F; Zhang L
Adv Sci (Weinh); 2023 May; 10(15):e2207366. PubMed ID: 36951547
[TBL] [Abstract][Full Text] [Related]
12. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy.
Sevcikova A; Izoldova N; Stevurkova V; Kasperova B; Chovanec M; Ciernikova S; Mego M
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008915
[TBL] [Abstract][Full Text] [Related]
13. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.
Di Modica M; Gargari G; Regondi V; Bonizzi A; Arioli S; Belmonte B; De Cecco L; Fasano E; Bianchi F; Bertolotti A; Tripodo C; Villani L; Corsi F; Guglielmetti S; Balsari A; Triulzi T; Tagliabue E
Cancer Res; 2021 Apr; 81(8):2195-2206. PubMed ID: 33483370
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance.
Mondal P; Meeran SM
Cancer Metastasis Rev; 2024 Mar; 43(1):135-154. PubMed ID: 37707749
[TBL] [Abstract][Full Text] [Related]
16. [The role of intestinal microbiota in the response to anti-tumor therapies].
Vétizou M; Daillère R; Zitvogel L
Med Sci (Paris); 2016 Nov; 32(11):974-982. PubMed ID: 28008838
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic properties of chemotherapy.
Fournier C; Rivera Vargas T; Martin T; Melis A; Apetoh L
Curr Opin Pharmacol; 2017 Aug; 35():83-88. PubMed ID: 28551360
[TBL] [Abstract][Full Text] [Related]
18. Xiao-Chai-Hu-Tang ameliorates tumor growth in cancer comorbid depressive symptoms via modulating gut microbiota-mediated TLR4/MyD88/NF-κB signaling pathway.
Shao S; Jia R; Zhao L; Zhang Y; Guan Y; Wen H; Liu J; Zhao Y; Feng Y; Zhang Z; Ji Q; Li Q; Wang Y
Phytomedicine; 2021 Jul; 88():153606. PubMed ID: 34111616
[TBL] [Abstract][Full Text] [Related]
19. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.
Panebianco C; Andriulli A; Pazienza V
Microbiome; 2018 May; 6(1):92. PubMed ID: 29789015
[TBL] [Abstract][Full Text] [Related]
20. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
